What is the mechanism of action of this treatment?

Pembrolizumab, a PD-1 inhibitor, enhances the immune system's ability to detect and destroy cancer cells by blocking the PD-1 pathway, which tumors often exploit to evade immune detection. This is particularly important for solid tumor patients as it can lead to better tumor control and improved survival rates. Other treatments like chemotherapy target rapidly dividing cells, and targeted therapies focus on specific genetic mutations within the tumor, offering a more personalized approach to cancer treatment. Understanding these mechanisms allows for more effective and tailored treatment strategies for patients with solid tumors.

What side effects are associated with this type of intervention?

Common side effects of PD-1 inhibitors like Pembrolizumab in the treatment of solid tumors include fatigue, rash, pruritus, diarrhea, and nausea. Severe adverse events can include pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. For novel agents with unknown mechanisms, such as OMTX705, side effects can vary but often include similar immune-related adverse events, as well as potential infusion-related reactions and organ-specific toxicities. It is essential for patients to discuss these potential side effects with their healthcare provider to manage and mitigate risks effectively.

What prior FDA approvals exist?

Pembrolizumab, a PD-1 inhibitor, has received FDA approval for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC), melanoma, and gastric cancer, among others. Other PD-1 inhibitors like Nivolumab have also been approved for similar indications. Additionally, combination therapies involving PD-1 inhibitors and other agents, such as chemotherapy or other immunotherapies, have been approved to enhance treatment efficacy. These approvals are based on clinical trials demonstrating improved overall survival and progression-free survival in patients with advanced or metastatic solid tumors.

What other types of research exist?

Promising alternatives to OMTX705 and pembrolizumab for solid tumors include: 1) Dostarlimab (Jemperli) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, 2) Lenvatinib plus pembrolizumab for advanced endometrial cancer with progression after platinum-based therapy, and 3) Enfortumab vedotin for advanced urothelial carcinoma after PD-1 or PD-L1 inhibitors. These treatments have shown efficacy in clinical trials and may be viable options in 2024.

← Back to Search

Monoclonal Antibodies

OMTX705 + Pembrolizumab for Cancer

Phase 1

Recruiting

Research Sponsored by Oncomatryx Biopharma S.L.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 24 months

Awards & highlights

Summary

This trial tests a new drug, OMTX705, alone or with pembrolizumab, in patients with advanced cancer who have no other treatment options. The study aims to find the safest dose and see if the combination works better than OMTX705 alone.

Who is the study for?

Adults with advanced or metastatic solid tumors without standard treatment options can join this trial. They must have measurable disease, good organ function, and an ECOG performance status of 0-1. Women who can bear children and men with partners who can must use contraception. Exclusions include active infections, certain heart conditions, pregnancy, recent other cancer treatments, uncontrolled brain metastases, and specific medication interactions.

What is being tested?

OMTX705 is being tested alone and combined with Pembrolizumab to treat advanced cancers in patients lacking other options. This Phase 1 study will gradually increase doses to find safe levels (dose-escalation) before expanding the number of participants at those levels (expansion phase).

What are the potential side effects?

Possible side effects may include reactions related to the immune system such as inflammation in various organs due to OMTX705 or Pembrolizumab's action on the body's defenses. Other common drug-related issues could be fatigue, digestive problems or changes in blood counts.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Safety evaluation of OMTX705

Secondary study objectives

Evaluation of OMTX705 Immunogenicity

Evaluation of the OMTX705 Pharmacokinetics

Exercise, Aerobic

Other study objectives

Evaluation of OMTX705 biomarkers

Evaluation of OMTX705 payload metabolites

Evaluation of QTc prolongation

+3 more

Side effects data

From 2022 Phase 1 & 2 trial • 35 Patients • NCT03003468

40%

FATIGUE

37%

INFUSION RELATED REACTION

37%

NAUSEA

23%

DIARRHEA

23%

BACK PAIN

23%

ABDOMINAL PAIN

23%

ANOREXIA

20%

COUGH

20%

ARTHRALGIA

20%

NON-CARDIAC CHEST PAIN

17%

DYSPNEA

17%

CONSTIPATION

17%

CHILLS

17%

MYALGIA

13%

DIZZINESS

13%

HEADACHE

13%

PRURITUS

13%

RASH MACULO-PAPULAR

10%

ANEMIA

10%

URTICARIA

10%

SINUS TACHYCARDIA

10%

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, SPECIFY

10%

EDEMA LIMBS

10%

ALLERGIC REACTION

10%

ANXIETY

10%

LUNG INFECTION

10%

SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY

EAR AND LABYRINTH DISORDERS - OTHER, SPECIFY

HYPERGLYCEMIA

PAIN

PELVIC PAIN

PRODUCTIVE COUGH

PLEURAL EFFUSION

VOICE ALTERATION

VOMITING

FEVER

FLATULENCE

TUMOR PAIN

CREATININE INCREASED

HYPERTHYROIDISM

NECK PAIN

DEPRESSION

FLU LIKE SYMPTOMS

LYMPHOCYTE COUNT DECREASED

DYSPEPSIA

FLUSHING

HYPONATREMIA

HYPOTHYROIDISM

URINARY TRACT INFECTION

ALKALINE PHOSPHATASE INCREASED

DYSPHAGIA

ESOPHAGITIS

GASTROESOPHAGEAL REFLUX DISEASE

OSTEONECROSIS OF JAW

BRONCHOSPASM

PNEUMONITIS

SORE THROAT

BLURRED VISION

GAIT DISTURBANCE

HEMORRHOIDS

POSTNASAL DRIP

PRESYNCOPE

ACUTE KIDNEY INJURY

PERIPHERAL MOTOR NEUROPATHY

DRY SKIN

FLASHING LIGHTS

HYPOMAGNESEMIA

MUSCLE WEAKNESS LOWER LIMB

HYPERTENSION

HYPOTENSION

SINUSITIS

SYNCOPE

HEARING IMPAIRED

RASH ACNEIFORM

SOMNOLENCE

COLITIS

HOT FLASHES

RESPIRATORY FAILURE

CONJUNCTIVITIS

MOVEMENTS INVOLUNTARY

NASAL CONGESTION

PARESTHESIA

VAGINAL INFECTION

GASTROINTESTINAL DISORDERS - OTHER, SPECIFY

NEUTROPHIL COUNT DECREASED

ALLERGIC RHINITIS

PAIN IN EXTREMITY

SEPSIS

BLOATING

DEHYDRATION

DRY MOUTH

INSOMNIA

MALAISE

PAIN OF SKIN

THROMBOEMBOLIC EVENT

TREMOR

WEIGHT GAIN

100%

80%

60%

40%

20%

Study treatment Arm

Imprime PGG 4 mg/kg

Imprime PGG 2 mg/kg

Trial Design

2Treatment groups

Experimental Treatment

Group I: Monotherapy (OMTX705)Experimental Treatment1 Intervention

OMTX705 is administered as single agent.

Group II: Combination (OMTX705 + pembrolizumab)Experimental Treatment2 Interventions

OMTX705 is administered in combination with pembrolizumab.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2070

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Pembrolizumab, a PD-1 inhibitor, enhances the immune system's ability to detect and destroy cancer cells by blocking the PD-1 pathway, which tumors often exploit to evade immune detection. This is particularly important for solid tumor patients as it can lead to better tumor control and improved survival rates. Other treatments like chemotherapy target rapidly dividing cells, and targeted therapies focus on specific genetic mutations within the tumor, offering a more personalized approach to cancer treatment. Understanding these mechanisms allows for more effective and tailored treatment strategies for patients with solid tumors.

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.New therapeutic strategies for malignant pleural mesothelioma.